MOB — Moberg Pharma AB (publ)

MOBMoberg Pharma AB (publ)

STO · SE · Healthcare · Drug Manufacturers - Specialty & Generic · mobergpharma.se

11.00SEK+0.73%Mkt Cap: 528.29M SEKP/E: —Last update: 2026-05-13

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly k…

Industry Peers

Drug Manufacturers - Specialty & Generic

SOBI

Swedish Orphan Biovitrum AB (publ)

153.14BSEKP/E 167.7

ECILC

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.

Turk Ilac Ve Serum Sanayi Anonim Sirketi

3.09BTRY—

ROVI

Laboratorios Farmaceuticos Rovi, S.A.

3.02BEURP/E 25.0

loading…

Indicators:|

Key Statistics

Valuation

P/E (Trailing)—

P/E (Forward)-56.20

PEG—

P/B0.58

P/SInfinity

EV/EBITDA-23.79

EV/Revenue—

EPS (TTM)-0.55

EPS (Forward)-0.20

Cash Flow & Leverage

FCF Yield—

FCF Margin—

Operating CF-17.49M SEK

CapEx (TTM)43.19M SEK

Net Debt/EBITDA0.58

Net Debt-11.89M SEK

Technical

SMA 5010.82 (+1.7%)

SMA 2009.491 (+15.9%)

Beta0.64

S&P 52W Chg24.23%

Avg Vol (30d)109.28K

Avg Vol (10d)80.00K

Technical Indicators

RSI (14)50.5

MACD0.0787

MACD Signal0.1690

MACD Hist.-0.0903

BB Upper12.49 SEK

BB Middle11.22 SEK

BB Lower9.941 SEK

BB Width22.74%

ATR (14)0.7608 SEK

Vol Ratio (20d)0.36x

52W Range

7.25055% of range14.12

52W High14.12 SEK

52W Low7.250 SEK

Profitability

Gross Margin56.73%

EBITDA Margin0.00%

Profit Margin-201.18%

Oper. Margin0.00%

ROE-4.09%

ROA-3.99%

Revenue Growth—

Earnings Growth—

Balance Sheet

Debt/Equity0.00

Current Ratio2.09

Quick Ratio0.27

Book Value/Sh19.53 SEK

Cash/Share0.4380 SEK

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 SEK

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div DateNov 4, 2019

Pay Date—

Splits

Last Split1:10

Split DateMay 24, 2023

Ownership

Shares Out.47.00M

Float40.40M

Insiders12.07%

Institutions21.70%

Analyst Consensus

Rating0.0 (Hold)

Target (Mean)14.00 SEK

Target Range14.00 SEK – 14.00 SEK

# Analysts1

Company

Market Cap528.29M SEK

Enterprise Value490.90M SEK

Revenue (TTM)0 SEK

Gross Profit7.68M SEK

Net Income (TTM)-27.24M SEK

Revenue/Share0.0000 SEK

Fiscal Year EndDec 2025

MR QuarterDec 2020

Employees11

Last Price11.00 SEK

CountrySE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISINUS61174X1090